Oracle will provide a platform that will enable the US government to run clinical trials to see if two malaria drugs should be approved to treating COVID-19, according to sources close to the discussions.
The New York Times reportedthat Oracle and the White House were in talks about the platform. ZDNet confirmed those talks.
Details about the Oracle platform are still being worked out, but the general sketch is that the platform would enable the Department of Health and Human Services, Food and Drug Administration and Centers for Medicare and Medicaid to analyze COVID-19 treatment with the malaria drugs.
Also:
President Trump has touted the use of the malaria drugs--chloroquine and hydroxychloroquine--against COVID-19. However, more testing is required. Oracle's platform would track treatments, collect data from the field and store information on patient symptoms.
This data repository will be critical to determining effectiveness of the pair of malaria drugs given most evidence is anecdotal at this time.The Centers for Disease Controlsaid the malaria drugs have been used on patients on an "uncontrolled basis in multiple countries."
More:
Comments
Post a Comment